@article {Ariano:2003:1088-5412:179,
title = "Specific Immunotherapy Effect on Interleukin-18 and CD30 Serum Levels in Monosensitized Patients with Rhinitis",
journal = "Allergy and Asthma Proceedings",
parent_itemid = "infobike://ocean/aap",
publishercode ="ocean",
year = "2003",
volume = "24",
number = "3",
publication date ="2003-05-01T00:00:00",
pages = "179-183",
itemtype = "ARTICLE",
issn = "1088-5412",
eissn = "1539-6304",
url = "https://www.ingentaconnect.com/content/ocean/aap/2003/00000024/00000003/art00006",
author = "Ariano, Renato and Merendino, Rosario A. and Minciullo, Paolo L. and Salpietro, Carmelo D. and Gangemi, Sabastiano",
abstract = "To clarify the immunologic changes associated with specific immunotherapy (SIT), we analyzed interleukin (IL)-18 and CD30 serum levels in a group of patients with allergic rhinitis before and after SIT. IL-18 is a proinflammatory cytokine that plays an important role in the Th1 response. CD30 is a marker of Th2 lymphocytes. We selected 16 healthy donors (HDs) and 16 patients affected by allergic rhinitis, matched for sex and age. Serum IL-18 and CD30 levels were assayed by an immunoenzymatic method. IL-18 serum levels in the patients were lower than in the HDs before SIT (200.69 \textpm 93.48 pg/mL versus 296.50 \textpm 66.29 pg/mL; p < 0.05). After SIT, patients showed an increase of serum IL-18 levels (288.69 \textpm 146.69 pg/mL versus 200.69 \textpm 93.48 pg/mL; p < 0.05). On the contrary, serum CD30 levels were higher in patients before SIT with respect to HDs (14.78 \textpm 8.30 IU/mL versus < 1 IU/mL; p < 0.05). SIT caused a decrease of serum CD30 levels in patients who were allergic (5.95 \textpm 5.70 IU/mL versus 14.78 \textpm 8.30 IU/mL; p < 0.05). In conclusion, in this study we showed for the first time the shift of IL-18 and CD30 production after SIT.",
}